Lovastatin + ezetimibe

1 paper1 finding

PubChem 53232 PubChem 150311 ChEBI 40303 ChEBI 49040

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Circulating IGF-1

downin mice1

1 study

Lovastatin + ezetimibe decreases circulating IGF-1 in mice.
“in vivo lovastatin and ezetimibe (LE) exposure increased hepatic SA-β-gal-positive area, elevated p21/p16 expression, and lowered circulating IGF-1.”
Animalsin vivo lovastatin and ezetimibe exposure
Statin-exposed liver cells impaired muscle formation in the lab
Cell death discovery10 Oct 2026

Latest

1 in 12 months

Cell Death Discovery5 h

Statin-exposed liver cells impaired muscle formation in the lab

Experiments with lab-grown liver and muscle cells linked statin exposure to lower levels of insulin-like growth factor-1, a growth signal.Experiments with lab-grown liver and muscle cells linked statin exposure to lower levels of insulin-like growth factor-1, a growth signal.

Experiments in animalsMuscle

Paper

Lovastatin + ezetimibe

Outcomes

Latest

Statin-exposed liver cells impaired muscle formation in the lab

Related